Emerging drugs for acute and chronic heart failure: current and future developments

Abstract

Heart failure continues to be a major public health issue. Although angiotensin-converting enzyme inhibitors and β-adrenergic blockers have been broadly used as evidence-based therapies in heart failure, morbidity and mortality remains high. Furthermore, treatment for acute decompensated heart failure and diastolic heart failure (or ‘heart failure with preserved ejection fraction’) is far from perfect. This review provides a broad overview of some of the novel compounds under investigation for the treatment of heart failure. Novel strategies include drugs that aim to alleviate congestion and improve hemodynamics, drugs that preserve renal function, drugs that reduce arterial and myocardial stiffness, drugs that module myocardial contractility, drugs that affect metabolic and hormonal balance, and drugs that act on existing and novel physiologic targets.

Keywords::

• cardiotonic agents/therapeutic use
• cardiovascular agents/pharmacology/therapeutic use
• congestive/drug therapy
• drug design
• heart failure